Novoprotein(SH:688137) Xin Lang Cai Jing·2025-10-13 01:41Core Insights - The stock of Nearshore Protein experienced a decline of 3.19% on October 10, with a trading volume of 26.32 million yuan [1] - The company reported a financing buy-in of 3.68 million yuan and a net financing buy of 849,000 yuan on the same day [1] - As of October 10, the total financing and securities lending balance for Nearshore Protein was 72.08 million yuan, representing 5.19% of its market capitalization [1] Financing and Securities Lending - On October 10, Nearshore Protein had a financing buy-in of 3.68 million yuan, with a total financing balance of 72.08 million yuan, which is above the 60th percentile level over the past year [1] - There were no securities lent or repaid on that day, indicating a high level of securities lending activity, with the balance at 0.00 yuan, exceeding the 90th percentile level over the past year [1] Company Overview - Nearshore Protein, established on September 7, 2009, is located in Suzhou, Jiangsu Province, and was listed on September 29, 2022 [1] - The company's main business includes the research, production, and sales of target and factor proteins, recombinant antibodies, enzymes, and reagents, along with related technical services [1] - The revenue composition is as follows: target and factor proteins 58.04%, enzymes and reagents 25.63%, CRO services 11.87%, recombinant antibodies 2.67%, and others 1.79% [1] Shareholder and Financial Performance - As of August 20, the number of shareholders for Nearshore Protein was 6,459, a decrease of 4.41%, while the average number of circulating shares per person increased by 4.61% to 5,058 shares [2] - For the first half of 2025, the company achieved a revenue of 72.09 million yuan, a year-on-year increase of 20.85%, but reported a net profit attributable to shareholders of -24.22 million yuan, a decrease of 172.00% year-on-year [2] Dividend and Institutional Holdings - Since its A-share listing, Nearshore Protein has distributed a total of 70.18 million yuan in dividends [3] - As of June 30, 2025, the top ten circulating shareholders included several institutional investors, with notable increases in holdings from certain funds [3]